We believe that safety concerns regarding prescription medications provide a significant opportunity for our products.
(PRWEB) January 8, 2007
Today's announcement is the culmination of years of research and work into the development of evidence-based nutraceutical preparations for the treatment of common chronic illnesses including ARTHROLEVE, the companies flagship blockbuster Arthritis treatment (http://www.universitylabtechnologies.com) product.
Evidence-based medicine/healthcare (http://www.universitylabtechnologies.com) is looked upon as a new paradigm, replacing the traditional medical paradigm which is based on authority. It is dependent on the use of randomized controlled trials, as well as systematic reviews (of a series of trials) and meta-analysis, although it is not restricted to these. There is also an emphasis on the dissemination of information, as well as its collection, so that the evidence can reach clinical practice. It therefore has commonality with the idea of research-based practice. It is also closely linked with the Cochrane Collaboration, which is a worldwide network of centers, whose aim is to promote and foster this approach.
Dr. Jarret Morrow, President and Chief Scientific Officer, was quoted as saying, "We are currently witnessing an explosion in the neutraceutical industry which, in part, reflects the growing skepticism of consumers towards pharmaceutical products following the withdrawal of such blockbuster pain medications as Vioxx (http://www.universitylabtechnologies.com) and Celebrex (http://www.universitylabtechnologies.com). In addition, the industry is currently in flux with a shift away from products which simply claim that their products work to those companies which prove they work."
The US joint pain market includes more than 43 million U.S. adults who suffer from arthritis and chronic pain. Approximately one-half of these individuals suffer from Osteoarthritis. In fact, four of five adults will suffer back pain at some point in their lifetime.
Dr. Morrow went on to say, "We believe that safety concerns regarding prescription medications provide a significant opportunity for our products."
The market for Vioxx(TM) and Celebrex(TM) drugs may have exceeded $5.0 billion per year prior to their respective recalls from the market. In light of these safety concerns, consumers may hesitate before switching to other related prescription products such as prescription and OTC NSAIDS.
About University Lab Technologies (http://www.universitylabtechnologies.com) -- Every year university labs around the globe identify research and test natural compounds and formulations which have the potential to improve the quality of our lives.
Over 98% of these potentially life changing discoveries are never commercialized for the benefit of the public.
University Lab Technologies, in collaboration with universities worldwide, researches and identifies those compounds that have proven evidence based effects and have the greatest potential for improving our lives.
University Lab Technologies' mission is the deliver the latest advances and discoveries in natural compounds packaged in our unique patented formulations delivered to satisfy the needs of consumers for the treatment of many common chronic ailments. http://www.universitylabtechnologies.com
Optimized by Newsforce